Global RNAi for Therapeutic Market Survey and Trend Research 2018

December 2017 | 82 pages | ID: G765C171C8CEN
99Strategy

Abstracts

Summary

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

This report describes the development of the industry by upstream & downstream, industry overall and development, key companies, as well as type segment & market application and so on, and makes a scientific prediction for the development industry prospects on the basis of analysis, finally, analyzes opportunities for investment in the industry at the end of the report.

Industry Chain

• Raw Materials
• Cost
• Technology
• Consumer Preference

Industry Overall:

• History
• Development & Trend
• Market Competition
• Trade Overview
• Policy

Region (North America, Europe, Asia-Pacific, South America, Middle East, Africa):

• Regional Market
• Production Development
• Sales
• Regional Trade
• Regional Forecast

Company (Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, RXi Pharmaceuticals, RXi Pharmaceuticals, miRagen Therapeutics, Gradalis, Sirnaomics etc.):

• Company Profile
• Product & Service
• Business Operation Data
• Market Share

Investment Analysis:

• Market Features
• Investment Opportunity
• Investment Calculation

Contents

PART 1 INDUSTRY OVERVIEW

1.1 RNAi for Therapeutic Industry
1.1.1 Definition
1.1.2 Industry Trend
1.2 Industry Chain
1.2.1 Upstream
1.2.2 Technology
1.2.3 Cost Structure
1.2.4 Consumer Preference
1.2.2 Downstream

PART 2 INDUSTRY OVERALL

2.1 Industry History
2.2 Development Prospect
2.3 Competition Structure
2.4 Relevant Policy
2.5 Trade Overview

PART 3 RNAI FOR THERAPEUTIC MARKET BY PRODUCT

3.1 Products List of Major Companies
3.2 Market Size
3.3 Market Forecast

4 KEY COMPANIES LIST

4.1 Alnylam Pharmaceuticals (Company Overview, Sales Data etc.)
4.1.1 Company Overview
4.1.2 Products and Services
4.1.3 Business Analysis
4.2 Arrowhead (Company Overview, Sales Data etc.)
4.2.1 Company Overview
4.2.2 Products and Services
4.2.3 Business Analysis
4.3 Dicerna Pharmaceuticals (Company Overview, Sales Data etc.)
4.3.1 Company Overview
4.3.2 Products and Services
4.3.3 Business Analysis
4.4 Mirna Therapeutics (Company Overview, Sales Data etc.)
4.4.1 Company Overview
4.4.2 Products and Services
4.4.3 Business Analysis
4.5 RXi Pharmaceuticals (Company Overview, Sales Data etc.)
4.5.1 Company Overview
4.5.2 Products and Services
4.5.3 Business Analysis
4.6 RXi Pharmaceuticals (Company Overview, Sales Data etc.)
4.6.1 Company Overview
4.6.2 Products and Services
4.6.3 Business Analysis
4.7 miRagen Therapeutics (Company Overview, Sales Data etc.)
4.7.1 Company Overview
4.7.2 Products and Services
4.7.3 Business Analysis
4.8 Gradalis (Company Overview, Sales Data etc.)
4.8.1 Company Overview
4.8.2 Products and Services
4.8.3 Business Analysis
4.9 Sirnaomics (Company Overview, Sales Data etc.)
4.9.1 Company Overview
4.9.2 Products and Services
4.9.3 Business Analysis

PART 5 MARKET COMPETITION

5.1 Companies Competition
5.2 Industry Competition Structure Analysis
5.2.1 Rivalry
5.2.2 Threat of New Entrants
5.2.3 Substitutes
5.2.4 Bargaining Power of Suppliers
5.2.5 Bargaining Power of Buyers

PART 6 MARKET DEMAND BY SEGMENT

6.1 Demand Situation
6.1.1 Industry Application Status
6.1.2 Industry SWOT Analysis
6.1.2.1 Strengths
6.1.2.2 Weaknesses
6.1.2.3 Opportunities
6.1.2.4 Threats
6.2 Major Customer Survey
6.3 Demand Forecast

PART 7 REGION OPERATION

7.1 Regional Market
7.2 Production and Sales by Region
7.2.1 Production
7.2.2 Sales
7.2.3 Trade
7.3 Regional Forecast

PART 8 MARKET INVESTMENT

8.1 Market Features
8.1.1 Product Features
8.1.2 Price Features
8.1.3 Channel Features
8.1.4 Purchasing Features
8.2 Investment Opportunity
8.2.1 Regional Investment Opportunity
8.2.2 Industry Investment Opportunity
8.3 Investment Calculation
8.3.1 Cost Calculation
8.3.2 Revenue Calculation
8.3.3 Economic Performance Evaluation

PART 9 CONCLUSION

List Of Tables

LIST OF TABLES

Table Global RNAi for Therapeutic Market 2012-2017, by Type, in USD Million
Table Global RNAi for Therapeutic Market 2012-2017, by Type, in Volume
Table Global RNAi for Therapeutic Market Forecast 2018-2023, by Type, in USD Million
Table Global RNAi for Therapeutic Market Forecast 2018-2023, by Type, in Volume
Table Alnylam Pharmaceuticals Overview List
Table RNAi for Therapeutic Business Operation of Alnylam Pharmaceuticals (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Arrowhead Overview List
Table RNAi for Therapeutic Business Operation of Arrowhead (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Dicerna Pharmaceuticals Overview List
Table RNAi for Therapeutic Business Operation of Dicerna Pharmaceuticals (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Mirna Therapeutics Overview List
Table RNAi for Therapeutic Business Operation of Mirna Therapeutics (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table RXi Pharmaceuticals Overview List
Table RNAi for Therapeutic Business Operation of RXi Pharmaceuticals (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table RXi Pharmaceuticals Overview List
Table RNAi for Therapeutic Business Operation of RXi Pharmaceuticals (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table miRagen Therapeutics Overview List
Table RNAi for Therapeutic Business Operation of miRagen Therapeutics (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Gradalis Overview List
Table RNAi for Therapeutic Business Operation of Gradalis (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Sirnaomics Overview List
Table RNAi for Therapeutic Business Operation of Sirnaomics (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Global RNAi for Therapeutic Sales Revenue 2012-2017, by Companies, in USD Million
Table Global RNAi for Therapeutic Sales Revenue Share, by Companies, in USD Million
Table Global RNAi for Therapeutic Sales Volume 2012-2017, by Companies, in Volume
Table Global RNAi for Therapeutic Sales Revenue Share, by Companies in 2017, in Volume
Table RNAi for Therapeutic Demand 2012-2017, by Application, in USD Million
Table RNAi for Therapeutic Demand 2012-2017, by Application, in Volume
Table RNAi for Therapeutic Demand Forecast 2018-2023, by Application, in USD Million
Table RNAi for Therapeutic Demand Forecast 2018-2023, by Application, in Volume
Table Global RNAi for Therapeutic Market 2012-2017, by Region, in USD Million
Table Global RNAi for Therapeutic Market 2012-2017, by Region, in Volume
Table RNAi for Therapeutic Market Forecast 2018-2023, by Region, in USD Million
Table RNAi for Therapeutic Market Forecast 2018-2023, by Region, in Volume

List Of Figures

LIST OF FIGURES

Figure RNAi for Therapeutic Industry Chain Structure
Figure Global RNAi for Therapeutic Market Growth 2012-2017, by Type, in USD Million
Figure Global RNAi for Therapeutic Market Growth 2012-2017, by Type, in Volume
Figure Global RNAi for Therapeutic Sales Revenue Share, by Companies in 2017, in USD Million
Figure Global RNAi for Therapeutic Sales Volume Share 2012-2017, by Companies, in Volume
Figure Production Development by Region
Figure Sales List by Region